This blog is meant to allow Fragment-based Drug Design Practitioners to get together and discuss NON-CONFIDENTIAL issues regarding fragments.
16 April 2019
Third fragment-based drug approved!
Last Friday the US FDA approved erdafitinib (Balversa) for certain bladder cancers with FGFR2 or FGFR3 mutations. Although the fragment-to-lead story has yet to be published, those of you who were fortunate enough to attend Fragments 2019 last month heard some of it from Harren Jhoti.
Congratulations to the folks at Astex and J&J for a new tool in the campaign against cancer!
And earlier in the pipeline, several more drugs have entered the clinic starting from fragments, taking the number above 45.